OBJECTIVE: To review the use of buprenorphine for opioid-addicted patients in primary care. QUALITY OF EVIDENCE: The MEDLINE database was searched for literature on buprenorphine from 1980 to 2009. Controlled trials, meta-analyses, and large observational studies were reviewed. MAIN MESSAGE: Buprenorphine is a partial opioid agonist that relieves opioid withdrawal symptoms and cravings for 24 hours or longer. Buprenorphine has a much lower risk of overdose than methadone and is preferred for patients at high risk of methadone toxicity, those who might need shorter-term maintenance therapy, and those with limited access to methadone treatment. The initial dose should be given only after the patient is in withdrawal. The therapeutic dose range for most patients is 8 to 16 mg daily. It should be dispensed daily by the pharmacist with gradual introduction of take-home doses. Take-home doses should be introduced more slowly for patients at higher risk of abuse and diversion (eg, injection drug users). Patients who fail buprenorphine treatment should be referred for methadone- or abstinence-based treatment. CONCLUSION: Buprenorphine is an effective treatment of opioid addiction and can be safely prescribed by primary care physicians.
OBJECTIVE: To review the use of buprenorphine for opioid-addictedpatients in primary care. QUALITY OF EVIDENCE: The MEDLINE database was searched for literature on buprenorphine from 1980 to 2009. Controlled trials, meta-analyses, and large observational studies were reviewed. MAIN MESSAGE: Buprenorphine is a partial opioid agonist that relieves opioid withdrawal symptoms and cravings for 24 hours or longer. Buprenorphine has a much lower risk of overdose than methadone and is preferred for patients at high risk of methadonetoxicity, those who might need shorter-term maintenance therapy, and those with limited access to methadone treatment. The initial dose should be given only after the patient is in withdrawal. The therapeutic dose range for most patients is 8 to 16 mg daily. It should be dispensed daily by the pharmacist with gradual introduction of take-home doses. Take-home doses should be introduced more slowly for patients at higher risk of abuse and diversion (eg, injection drug users). Patients who fail buprenorphine treatment should be referred for methadone- or abstinence-based treatment. CONCLUSION:Buprenorphine is an effective treatment of opioid addiction and can be safely prescribed by primary care physicians.
Authors: David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler Journal: Ann Fam Med Date: 2007 Mar-Apr Impact factor: 5.166
Authors: M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor Journal: Health Technol Assess Date: 2007-03 Impact factor: 4.014
Authors: Johan Kakko; Leif Grönbladh; Kerstin Dybrandt Svanborg; Joachim von Wachenfeldt; Christian Rück; Bob Rawlings; Lars-Håkan Nilsson; Markus Heilig Journal: Am J Psychiatry Date: 2007-05 Impact factor: 18.112
Authors: Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld Journal: J Gen Intern Med Date: 2007-04 Impact factor: 5.128
Authors: Daniel P Alford; Colleen T LaBelle; Jessica M Richardson; James J O'Connell; Carole A Hohl; Debbie M Cheng; Jeffrey H Samet Journal: J Gen Intern Med Date: 2007-02 Impact factor: 5.128
Authors: Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham Journal: J Behav Health Serv Res Date: 2017-07 Impact factor: 1.505
Authors: G Cristina Brailoiu; Elena Deliu; Robert Hooper; Nae J Dun; Ashiwel S Undieh; Martin W Adler; Khalid Benamar; Eugen Brailoiu Journal: Drug Alcohol Depend Date: 2011-12-21 Impact factor: 4.492
Authors: Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer Journal: Pain Date: 2013-05-07 Impact factor: 6.961
Authors: Traci R Rieckmann; Amanda J Abraham; Anne E Kovas; Bentson H McFarland; Paul M Roman Journal: Addict Behav Date: 2014-02-07 Impact factor: 3.913
Authors: Therese A Kosten; Xiaoyun Y Shen; Patrick W O'Malley; Berma M Kinsey; Ernest D Lykissa; Frank M Orson; Thomas R Kosten Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2013-06-02 Impact factor: 5.067